Asif Hameed Khan

Asif Hameed Khan

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Asif Hameed Khan

Global Medical, Sanofi, Bridgewater, NJ, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
MCMario Castro
Mario Castro
JCJonathan Corren
Jonathan Corren
IPIan D. Pavord
Ian D. Pavord
JMJorge Maspero
Jorge Maspero
SWSally Wenzel
Sally Wenzel
ATAriel Teper
Ariel Teper
Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.

28 June 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
KRKlaus F. Rabe
Klaus F. Rabe
PNParameswaran Nair
Parameswaran Nair
GBGuy Brusselle
Guy Brusselle
JMJorge F. Maspero
Jorge F. Maspero
MCMario Castro
Mario Castro
ATAriel Teper
Ariel Teper
Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unknown.

5 February 2019 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
NBNeil Bhattacharyya
Neil Bhattacharyya
SVSara Villeneuve
Sara Villeneuve
VJVijay N. Joish
Vijay N. Joish
CACaroline Amand
Caroline Amand
LMLeda Mannent
Leda Mannent
AKAsif Khan
Asif Khan
Objectives/Hypothesis: Establish treatment patterns and economic burden in US patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) versus without chronic rhinosinusitis (CRS). Determine comparative costs of subgroups with high clinical burden.Study Design: Observational, retrospective, case‐control study.Methods: This study matched patients with CRSwNP to patients without CRS (1:1) using the Truven Health MarketScan US claims database. Categorical and continuous variables were compared using McNemar test and paired t test (normal distribution) or Wilcoxon signed rank tests (non‐normal distribution). Within subgroups, χ2 and Wilcoxon or t tests were used (normal distribution).Results: There were 10,841 patients with CRSwNP and 10,841 patients without CRS included. Mean age in the CRSwNP cohort was 45.8 years; 56.2% were male. During follow‐up, patients with CRSwNP had an increased diagnosis of asthma versus patients without CRS (20.8% vs. 8.1%, respectively; P < .001). Annual incremental costs were $11,507 higher for patients with CRSwNP versus those without CRS. Costs were higher in subgroups of patients with CRSwNP undergoing functional endoscopy sinus surgery (FESS), with a comorbid diagnosis of asthma, receiving oral corticosteroids, or macrolides versus the overall CRSwNP group. Patients with CRSwNP undergoing FESS had the highest costs of the four subgroups ($26,724, $22,456, $20,695, and $20,990, respectively).Conclusions: Annual incremental costs were higher among patients with CRSwNP versus without CRS. Patients with CRSwNP with high clinical burden had higher overall costs than CRSwNP patients without.Level of Evidence: NALaryngoscope, 129:1969–1975, 2019

1 February 2019 in Rhinology journal
Verified
Journal Article
Closed access
AKA. Khan
A. Khan
GVG. Vandeplas
G. Vandeplas
THT.M.T. Huynh
T.M.T. Huynh
VJV.N. Joish
V.N. Joish
LML. Mannent
L. Mannent
CBC. Bachert
C. Bachert
Chronic rhinosinusitis (CRS) is a common yet under-recognised chronic inflammatory disease of the nose and paranasal sinuses that is classified according to the presence (CRSwNP) or absence (CRSsNP) of nasal polyps. This paper reports the methodology and descriptive results of the Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort. We established a large CRS cohort within the GALEN consortium (European FP6 research initiative) to identify inflammatory endotypes, the natural disease course, and its impact on health-related quality of life (HRQoL). Detailed information on the impact of CRS on HRQoL, comorbidity incidence, objective disease measures, and medical and surgical treatments were collected. This multicentre cross-sectional case-control study recruited 935 adults (869 eligible for analysis: 237 CRSsNP; 445 CRSwNP; 187 controls [reference group]). Comorbidities such as asthma, allergy, eczema, food allergy, urticaria, and chronic obstructive pulmonary disease were significantly more frequent in CRS patients. Nasal corticosteroids, antibiotics, and oral corticosteroids were the most common treatments. Significantly more CRSwNP patients reported previous sinonasal surgery. This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient distribution of this study does not necessarily reflect disease distribution in the general population.

1 September 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
TLTanya M. Laidlaw
Tanya M. Laidlaw
JMJoaquim Mullol
Joaquim Mullol
CFChunpeng Fan
Chunpeng Fan
DZDonghui Zhang
Donghui Zhang
NANikhil Amin
Nikhil Amin
LMLeda P. Mannent
Leda P. Mannent

26 August 2021 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
AKAsif H. Khan
Asif H. Khan
MRMatthew Reaney
Matthew Reaney
IGIsabelle Guillemin
Isabelle Guillemin
LNLauren Nelson
Lauren Nelson
SQShanshan Qin
Shanshan Qin
CHClaire Hopkins
Claire Hopkins
Objectives/Hypothesis: The 22‐item Sinonasal Outcome Test (SNOT‐22) is a validated chronic rhinosinusitis health‐related quality‐of‐life outcome (HRQoL) measure; however, SNOT‐22 domains have not been validated specifically for chronic rhinosinusitis with nasal polyps (CRSwNP).Study Design: Validation of SNOT‐22 domain structure, using data from 3 randomized, placebo‐controlled, double‐blinded, multicenter clinical trials of dupilumab in adults with moderate‐to‐severe CRSwNP.Methods: Preliminary dimensional structure was derived by exploratory factor analyses of SNOT‐22 data from a phase 2 trial (NCT01920893) of dupilumab for the treatment of CRSwNP. Data from 2 phase 3 clinical trials (NCT02912468 and NCT02898454) were then used for confirmatory factor analysis, and evaluated for reliability, construct validity, and responsiveness. In all three trials, the SNOT‐22 was administered electronically on a tablet and trial participants were required to answer all items.Results: Factor analysis supported five domains: Nasal, Ear/Facial, Sleep, Function, and Emotion. Correlations between domains were moderate to high, ranging from 0.53 (Nasal–Emotion) to 0.88 (Function–Sleep). Construct validity was mostly supported; relationships with other measures were almost always in the intended direction and magnitude. Internal consistency reliability also confirmed questionnaire structure with strong Cronbach's alpha values (all >0.80). Moderate‐to‐high correlations were observed between change in SNOT‐22 domain scores and other study patient‐reported outcome measures, along with large effect‐size estimates (≥0.7), demonstrating responsiveness of the Nasal, Sleep, and Function domains. Emotion and Ear/Facial domains had small‐to‐moderate effect sizes.Conclusions: Psychometric analyses support the validity, reliability, and responsiveness of five domains of SNOT‐22 (Nasal, Ear/Facial, Sleep, Function, and Emotion) for assessing symptoms and impact on HRQoL in patients with CRSwNP. Laryngoscope, 132:933–941, 2022